fate therapeutics stock price target

ET by Tonya Garcia Barrons. News in other languages on FATE THERAPEUTICS INC.

Fate Stock Price And Chart Nasdaq Fate Tradingview

Analyst ratings historical stock prices earnings estimates actuals.

. Ad Our Strong Buys Double the SP. In comparison to the median Healthcare stock FATEs pricesales ratio is 11793 higher now standing at 1452. Company Releases for Fate Therapeutics Inc.

Morgan Stanley Adjusts Fate. On average they expect Fate Therapeutics stock price to reach 10329 in the next twelve months. HC Wainwright restated a buy rating and issued a 12200 target price on shares of Fate Therapeutics in a research report on Tuesday January 11th.

Their forecasts range from 6000 to 14500. Stocks similar to Fate Therapeutics Inc in the Pharmaceutical. FATE has a higher upside potential average analyst target price relative to current price than 100215 of stocks in the mid market cap category.

Find the latest Fate Therapeutics Inc FATE stock price forecast 12-month price target predictions and analyst recommendations. The minimum target price for Fate Therapeutics analysts is 9858. Over the past 96 months FATEs priceearnings ratio has gone down 256.

Fate Therapeutics Inc. Wednesday February 16 2022. FATE a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer today announced that the Company will present at the following upcoming investor conferences.

The 19 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 10900 with a high estimate. Based On Fundamental Analysis. Morgan Stanley Adjusts Fate Therapeutics Price Target to 62 From 74 Maintains Equal.

Over the past 96 months FATEs pricesales ratio has gone. Truist Financial analyst R. Guggenheim Adjusts Price Target for Fate Therapeutics to 78 From 107 Maintains Buy Rati.

1 day agoSAN DIEGO March 02 2022 GLOBE NEWSWIRE -- Fate Therapeutics Inc. Learn more on FATEs analyst rating history. Fate Therapeutics upgraded to outperform from neutral at Wedbush price target raised to 74 from 71 Dec.

Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. FATE Evolution of the average Target Price on FATE THERAPEUTICS INC. With a target price of 8500 there is potential for a 168393 increase which would mean more than doubling the current price of 3167 for Fate Therapeutics Inc.

The average twelve-month price target for Fate Therapeutics is 10329 with a high price target of 14500 and a low price target of 6000. According to the issued ratings of 13 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 11 buy ratings for FATE. FATE updated stock price target summary.

9 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 10311 with the highest FATE stock price forecast at 13000 and the lowest FATE stock price forecast at 7400. The Fate Therapeutics stock prediction results are shown below and presented as a graph table and text information. The Company or Fate Therapeutics NASDAQ.

Today 200 Day Moving Average is the resistance level 6881. In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is greater than 94038 of that group. Sign in to your SmartPortfolio to see more analyst recommendations.

The minimum target price for Fate Therapeutics analysts is 10132. The average price target is 000 with a high estimate of 000 and a low estimate of 000. 15 2021 at 829 am.

Recommendations Chart FATE THERAPEUTICS INC. 50 Day Moving Average is the support level 5096. HC Wainwright Adjusts Price Target on Fate Therapeutics to 122 From 121 Maintains Bu.

NASDAQFATE Get Rating Equities researchers at Truist Financial issued their Q3 2022 earnings per share estimates for shares of Fate Therapeutics in a research note issued on Monday February 28th. Fate Therapeutics stock price target raised to 65 from 40 at Truist MarketWatch. 13 brokerages have issued 12 month target prices for Fate Therapeutics stock.

Tuesday March 03 2020. Analyst Recommendations on FATE THERAPEUTICS INC. 67 rows On Jan 11 2022 HC Wainwright gave 12200 rating for FATE.

Karnauskas expects that the biopharmaceutical company will earn 091 per share for the. Analyst Recommendations on FATE THERAPEUTICS INC. Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.

Our community identified positive and negative aspects for. Morgan Stanley lowered their target price on Fate Therapeutics from 7400 to 6200 and set an equal weight rating on the stock in a research report on Wednesday December 15th. Fate Therapeutics stock price target raised to 37 from 27 at Stifel Nicolaus MarketWatch.

CFO of Fate Therapeutics Inc 30-Year Financial Insider Trades Edward J Dulac Iii insider trades sold 15977 shares of FATE on 12202021 at an average price of 60 a share.

Fate Stock Price And Chart Nasdaq Fate Tradingview